Do solitary pancreatic metastases of renal-cell carcinoma indicate an indolent disease with a strong indication for aggressive local treatment? A case report with literature review

Abstract

Renal-cell carcinoma (RCC) most often metastasizes to the lungs, liver, and brain. Metastases of RCC to the pancreas are very rare. In the last decade, only a few cases of metachronous metastasis of kidney cancer to the pancreas have been reported in the literature. This article presents a case report of a 75-year-old female patient with a 16-year history of treatment of clear-cell carcinoma of the kidney, in whom pancreatic metastases were detected twice. Renal-cell carcinoma may have an indolent course with late relapse or may show dissemination. It is important to establish new recommendations for long-term follow-up in patients after radical treatment.

Genetic and Epigenetic Characteristics in Isolated Pancreatic Metastases of Clear-Cell Renal Cell Carcinoma

“…Further evidence for the high genetic stability of this entity is provided by reports of subsequent tumour progression after isPMRCC therapy, which occurred in 43% of 288 case reports after a median interval of 29.8 months [106], and 15.3% of these appeared as further isPMRCC in the pancreas remnant [2,20,30,46,56,[112][113][114][115][116][117][118][119][120]. In institutional communications, the incidence of newly isolated PM is estimated to be between 9% and 62% (median 27%) [2][3][4]7,9,10,12,45,112,113].…”

“…Numerous studies have so far dealt with this disease, partly in the form of case studies, or in the form of institutional experience reports, of which 1470 observations were reported by 2022 [1], to which 259 isPMRCC have since been added [2,3,[45][46][47][48][49][50][51][52][53][54][55][56], bringing the total number to 1729.…”